Listen to the article
The U.S. Food and Drug Administration has declined to review Moderna’s application for a new mRNA-based influenza vaccine, a move that signals increasing scrutiny of vaccine technologies under Health Secretary Robert F. Kennedy Jr.’s leadership.
Moderna announced Tuesday it had received a “refusal-to-file” letter from the FDA regarding its application for the novel flu vaccine developed using the same Nobel Prize-winning messenger RNA technology behind its COVID-19 vaccine.
The FDA’s decision centers on concerns about the company’s 40,000-person clinical trial methodology. In the letter, FDA vaccine director Dr. Vinay Prasad stated the agency does not consider the application to contain an “adequate and well-controlled trial” because it failed to compare the new vaccine against “the best-available standard of care in the United States at the time of the study.”
Moderna contends that prior to Kennedy’s appointment, FDA officials had approved its study design. According to the company, the FDA had previously indicated that while another brand specifically recommended for seniors would be preferred for participants 65 and older, the standard-dose flu shot Moderna had selected for comparison was acceptable. The company also noted it had shared additional data from a separate trial comparing its vaccine against a high-dose shot licensed for seniors.
“The FDA did not identify any safety or efficacy concerns with our product,” Moderna CEO Stephane Bancel said in a statement, adding that the decision “does not further our shared goal of enhancing America’s leadership in developing innovative medicines.”
Industry experts note that refusal-to-file decisions are rare in vaccine development, particularly after companies and FDA staff typically engage in extensive discussions over months or years before formal submission. Moderna has requested an urgent meeting with the FDA and noted that it has already applied for approval of the vaccine in Europe, Canada, and Australia.
The rejection comes amid growing tension between the biotech industry and Kennedy’s health department. Since Kennedy’s appointment, FDA officials have rolled back recommendations for COVID-19 vaccines, added additional warnings to mRNA-based COVID vaccines, and removed critics of the administration’s approach from an FDA advisory panel.
Kennedy, a longtime vaccine skeptic before joining the administration, announced last year that his department would cancel more than $500 million in contracts and funding for the development of vaccines using mRNA technology. This decision raised concerns in the scientific community about politicization of vaccine science and potential impacts on public health preparedness.
The dispute also highlights a significant shift in the FDA’s approach to vaccine evaluation. For decades, the agency has permitted vaccine manufacturers to update annual flu shots quickly by demonstrating they trigger an immune response in patients, rather than requiring lengthy studies tracking flu infection rates and outcomes. However, in an internal memo last year, Prasad indicated this streamlined approach would no longer be permitted—a stance that prompted more than a dozen former FDA commissioners to publish an editorial condemning the change.
The regulatory hurdle for Moderna’s flu vaccine comes at a critical time for the company, which has been working to diversify its product portfolio beyond COVID-19 vaccines. The mRNA technology, which instructs cells to produce proteins that trigger an immune response rather than introducing a weakened pathogen, has been heralded as a potential breakthrough for vaccine development across numerous diseases.
Moderna’s trial had concluded that its new mRNA-based flu vaccine was somewhat more effective in adults 50 and older compared to standard flu vaccines currently on the market.
AI tone detection: False
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
13 Comments
Interesting development on the Moderna flu vaccine application. The FDA’s concerns about the trial methodology seem reasonable, though it’s noteworthy that the agency had previously approved the study design. Looking forward to seeing how Moderna responds and if they can address the FDA’s issues.
Yes, the FDA’s stance appears to be driven by a heightened scrutiny of vaccine technologies under the new leadership. It will be important to see if Moderna can modify the trial to satisfy the agency’s standards.
The FDA’s decision to refuse Moderna’s application raises important questions about the regulatory landscape for novel vaccine technologies like mRNA. While patient safety should be the top priority, the process also needs to balance innovation and timely access to new therapies.
Agreed. This situation highlights the delicate balance regulators must strike between rigor and flexibility when evaluating emerging vaccine platforms. Transparent collaboration between Moderna and the FDA will be crucial moving forward.
As an investor, I’m curious to see how this setback affects Moderna’s broader pipeline and stock performance. The company has been a leader in mRNA technology, so this decision by the FDA could have wider implications for the sector.
That’s a good point. Moderna’s success has been closely tied to its mRNA expertise, so this regulatory hurdle may raise concerns about the company’s ability to navigate the approval process for future mRNA-based products.
The FDA’s decision on Moderna’s flu vaccine application raises important questions about the balance between innovation and regulatory oversight. While patient safety must come first, it’s crucial that the approval process remains fair and transparent for all vaccine developers.
Well said. Maintaining public trust in the regulatory system is critical, especially for emerging technologies like mRNA vaccines. A collaborative approach between Moderna and the FDA will be essential moving forward.
This news on the Moderna flu vaccine is a reminder that even innovative companies face scrutiny from regulators. The FDA’s focus on ensuring adequate clinical trial design is understandable, though the timing under the new administration is noteworthy.
The FDA’s decision to refuse Moderna’s flu vaccine application highlights the importance of robust clinical trial data, especially for novel vaccine technologies. While disappointing for the company, it’s crucial that regulators maintain high standards to protect public health.
Absolutely. Upholding safety and efficacy should be the top priority, even if it means additional hurdles for innovative vaccine developers like Moderna. The public trust in these new platforms is paramount.
As an investor, I’ll be closely monitoring how this situation with Moderna’s flu vaccine unfolds. The company’s success has been closely tied to its mRNA platform, so this regulatory hurdle could have broader implications for the industry.
This news on the Moderna flu vaccine is an interesting development in the broader context of the evolving regulatory landscape for mRNA-based products. It will be worth following how the company responds and whether they can address the FDA’s concerns.